In April 2017, the FDA approved the first-ever drug treatment for the rare and aggressive skin cancer Merkel cell carcinoma (MCC). The immunotherapy drug avelumab (Bavencio, EMD Serono/Pfizer) was approved based on the results of a multicenter, open-label, phase 2 trial as well as data from a real-world retrospective analysis of patients with metastatic MCC treated with chemotherapy.
Real-world Research
Ontada's research expertise covers the entire process, from proposal to publication, with clinical support from practicing oncologists acting as principal investigators, research support from Ontada's Medical Office, and researchers with over 350 real-world publication contributions
Genospace
Cancer care usually happens outside of experimental settings, but patient genomic data isn't commonly used to make decisions. Genospace uses patient data from next-generation sequencing to create market reports. Real-world evidence is vital to understanding genomics in cancer progression and therapeutic interaction.
In the News
Our thought leaders share expertise, research, and insights in top oncology publications. Join us to stay updated on cancer care advancements.
Press Releases
Keep yourself informed about the most recent news and announcements from Ontada. Discover the latest developments in oncology research and healthcare solutions.
Events
Join Ontada at oncology conferences across the country to see how our data, research, and provider education solutions can help your company advance cancer care
Upcoming Event
Visit Ontada at Booth 635 at the upcoming Summit for Clinical Ops Executives (SCOPE) conference in Orlando on Feb 3 – 6, 2025, to discover our offerings of real-world data, research and provider education.
Company
Ontada, whose name is a combination of “oncology” and “data,” was formed with the vision that transforming cancer care requires speed. Our commitment is to provide the most current evidence in oncology treatment so insights can be generated faster.
Leadership Team
Ontada is on a mission to transform cancer care and improve the lives of patients, setting new standards in the integration of research and clinical practice to generate real-world data, insights and evidence. Meet our team leading the way.
Careers
We need smart, ambitious and empathetic people to help us build the future of cancer treatment. Join us on the frontline of oncology innovation.
MCC Rx Marks First Use of Real-World Data for FDA Approval
In April 2017, the FDA approved the first-ever drug treatment for the rare and aggressive skin cancer Merkel cell carcinoma (MCC). The immunotherapy drug avelumab (Bavencio, EMD Serono/Pfizer) was approved based on the results of a multicenter, open-label, phase 2 trial as well as data from a real-world retrospective analysis of patients with metastatic MCC treated with chemotherapy.
By Clinical Oncology News September 13, 2018
Categories